X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf170 ↗Kurz gefasst
Leitlinie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Aliya A Khan und 43 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, McMaster University, Hamilton, ON L8S 4L8, Canada. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, McMaster University, Calcium disorders clinic.
Abstract (Originalsprache)
Purpose
An international working group (IWG) consisting of experts in X-linked hypophosphatemia (XLH) developed global guidelines providing a comprehensive, evidence-based approach to XLH diagnosis, management, and monitoring.
Methods
The IWG, consisting of 43 members as well as methodologists and a patient partner, conducted 2 systematic reviews (SRs) and narrative reviews to address key areas. The SRs addressed the impact of burosumab compared to conventional therapy (phosphate and active vitamin D) or no therapy on patient-important outcomes in adults. They also evaluated conventional therapy compared to no therapy. GRADE methodology was applied to evaluate the certainty of evidence. Non-GRADED recommendations were made in the presence of insufficient evidence to conduct SRs. These guidelines have been reviewed and endorsed by several medical and patient societies and organizations.
Results
The diagnosis of XLH is based on integrating clinical evaluation, laboratory findings confirming renal phosphate wasting (following exclusion of conditions mimicking XLH), and skeletal imaging. Fibroblast growth factor 23 measurement and DNA analysis are of value in the diagnosis, if available. Pathogenic or likely pathogenic variants in the PHEX gene are confirmatory but not necessary for the diagnosis. Management requires a multidisciplinary team knowledgeable and experienced in XLH. Effective medical therapy with burosumab can improve fracture and pseudofracture healing. Main Conclusion In adults with XLH and fractures or pseudofractures, burosumab is recommended over no therapy (strong recommendation, GRADEd). Additionally, burosumab is suggested as the preferred treatment compared to conventional therapy (conditional recommendation, GRADEd) in the absence of fractures or pseudofractures. If burosumab is not available, symptomatic adults should be treated with conventional therapy (Non-GRADEd recommendation).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, McMaster University, Hamilton, ON L8S 4L8, Canada.
- Department of Internal Medicine, Division of Endocrinology, Center for Bone Quality, Leiden University Medical Center, Leiden 2300 ZA, the Netherlands.
- Departments of Pediatrics (Endocrinology), and Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, CT 06520, USA.
- Department of Oral Medicine, Faculty of Dentistry, UMR 1333, Université Paris Cité, Paris 75006, France.
- Institut Imagine, INSERM 1163, 75015 Paris, France.
- Department of Oral Medicine, APHP, Paris 75006, France.
ORCID-Profile: Aliya A Khan, Dalal S Ali, Natasha M Appelman-Dijkstra, Thomas O Carpenter, Catherine Chaussain, Erik A Imel, Suzanne M Jan de Beur, Pablo Florenzano, Hajar Abu Alrob, R Todd Alexander, Farah Alsarraf, Signe Sparre Beck-Nielsen, Martin Biosse-Duplan, Martine Cohen-Solal, Rachel K Crowley, Karel Dandurand, Guido Filler, Lisa Friedlander, Seiji Fukumoto, Claudia Gagnon, Paul Goodyer, Corinna Grasemann, Chelsey Grimbly, Salma Hussein, Muhammad K Javaid, Sarah Khan, Aneal Khan, Anna Lehman, Willem F Lems, E Michael Lewiecki, Ciara McDonnell, Reza D Mirza, Emmett Morgante, Anthony A Portale, Yumie Rhee, Eric T Rush, Heide Siggelkow, Sotirios Tetradis, Laura Tosi, Leanne M Ward, Gordon Guyatt, Maria Luisa Brandi
Förderung
- NIDDK NIH HHS
- McMaster University
- Calcium disorders clinic
Zitieren
APA
Khan, A. A., Ali, D. S., Appelman-Dijkstra, N. M., Carpenter, T. O., Chaussain, C., Imel, E. A., Jan de Beur, S. M., Florenzano, P., Abu Alrob, H., Aldabagh, R., Alexander, R. T., Alsarraf, F., Beck-Nielsen, S. S., Biosse-Duplan, M., Cohen-Solal, M., Crowley, R. K., Dandurand, K., Filler, G., Friedlander, L., …, & Brandi, M. L. (2025). X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf170
Vancouver
Khan AA, Ali DS, Appelman-Dijkstra NM, Carpenter TO, Chaussain C, Imel EA, et al. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf170
BibTeX
@article{Khan2025,
author = {Khan, Aliya A and Ali, Dalal S and Appelman-Dijkstra, Natasha M and Carpenter, Thomas O and Chaussain, Catherine and Imel, Erik A and Jan de Beur, Suzanne M and Florenzano, Pablo and Abu Alrob, Hajar and Aldabagh, Rana and Alexander, R Todd and Alsarraf, Farah and Beck-Nielsen, Signe Sparre and Biosse-Duplan, Martin and Cohen-Solal, Martine and Crowley, Rachel K and Dandurand, Karel and Filler, Guido and Friedlander, Lisa and Fukumoto, Seiji and Gagnon, Claudia and Goodyer, Paul and Grasemann, Corinna and Grimbly, Chelsey and Hussein, Salma and Javaid, Muhammad K and Khan, Sarah and Khan, Aneal and Lehman, Anna and Lems, Willem F and Lewiecki, E Michael and McDonnell, Ciara and Mirza, Reza D and Morgante, Emmett and Morrison, Archibald and Portale, Anthony A and Rhee, Yumie and Rush, Eric T and Siggelkow, Heide and Tetradis, Sotirios and Tosi, Laura and Ward, Leanne M and Guyatt, Gordon and Brandi, Maria Luisa},
title = {X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf170}
}
EUVIMED